You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

  1. Developing a new treatment for MS: Controlling CD40 in EAE

    SBC: Op-T-Mune, Inc            Topic: NIAID

    DESCRIPTION (provided by applicant): The National Multiple Sclerosis (MS) Society reports that 1.2 million people worldwide and more than 400,000 people in the U.S. have clinically diagnosed MS. Currently there are 10 FDA approved drugs for MS but none ofthe current drugs have impacted the course of MS to prevent relapses or progression of disease. An efficient means to control the autoimmune infl ...

    STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  2. AutoRegister: A system for enhancing the accuracy of tumor change detection

    SBC: CORTICOMETRICS LLC            Topic: NCI

    DESCRIPTION (provided by applicant): This project proposes to build an integrated software-based system for enhancing the accuracy of tumor change detection. The intent of the system, called AutoRegister, which is to be deployed on a clinical magnetic resonance imaging (MRI) scanner platform, is to automate the alignment of a patient's brain scan with that of a prior scan, such that subseque ...

    STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  3. Second generation MTI-101 analogs using a novel peptoid-peptide hybrid beta-hairp

    SBC: MODULATION THERAPEUTICS, INC.            Topic: NCI

    MTI-101 is a cyclic beta-hairpin peptide that binds CD44 with high affinity and kills multiple myeloma cell lines in vitro and blocks the growth of myeloma tumors in 2 different murine models. This interaction of MTI-101 with the surface of MM cells causesprogrammed cell necrosis, whereas all approved MM drugs cause apoptosis and so the novel mechanism of MTI-101 or MTI-like compounds makes it esp ...

    STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  4. Prevention of erectile dysfunction following prostate cancer radiotherapy

    SBC: HUMANETICS CORP            Topic: NCI

    DESCRIPTION (provided by applicant): The aim of this proposal is to evaluate BIO 300 as an effective therapy to prevent and/or mitigate the erectile dysfunction (ED) that is commonly observed following radiotherapy (RT) for prostate cancer. Prostate cancer is the most common cancer among men in the United States. Approximately half of prostate cancer patients will undergo RT as a part of thei ...

    STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  5. MDCT Quantification of hepatic tumor viability for assessment of cancer therapy

    SBC: IQ MEDICAL IMAGING LLC            Topic: NCI

    DESCRIPTION (provided by applicant): Hepatocellular carcinoma (HCC) is the most common primary hepatic malignancy (more than 80%) and the third most common cause of death from cancer worldwide. Contrast-enhanced multi-phase multi-detector CT (MDCT) is a routine imaging modality for patients diagnosed with hepatic malignancy. The change of tumor size measured on single-phase (mostly portal-venous p ...

    STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  6. A smart needle guide template for MRI-guided transperineal prostate biopsy

    SBC: PHYSICAL SCIENCES INC.            Topic: NCI

    DESCRIPTION (provided by applicant): Physical Sciences Inc. (PSI) and the Surgical Navigation and Robotics Laboratory (SNR) at Brigham and Women's Hospital (BWH) propose to develop and test a Smart Template to guide transperineal targeted prostate biopsiesand subsequent therapy under magnetic resonance imaging (MRI). The project aims to solve the problem of poor diagnostic yield in prostate b ...

    STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  7. Cathepsin Inhibitors for Treatment of Breast Cancer Induced Bone Pain

    SBC: VIROBAY, INC.            Topic: NCI

    DESCRIPTION (provided by applicant): The World Health Organization estimates that the number of women living with breast cancer globally will rise to 15 million by the year 2020 with a significant portion of these patients in advanced stages of the disease. Breast cancer is the most frequent malignant tumor in women in the U.S. with nearly 200,000 women diagnosed each year. The U.S. NIH estimate o ...

    STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  8. Real-time bioimpedance based biopsy device

    SBC: RYTEK MEDICAL INC            Topic: NCI

    DESCRIPTION (provided by applicant): Over the last three decades the number of men diagnosed with prostate cancer has increased 85% as a result of new screening and diagnostic tools. However, a significant number of these newly diagnosed men are harboringclinically insignificant disease, which means that they are not likely to die from prostate cancer. A difficul decision facing urologists daily i ...

    STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  9. Lateral Flow Immunoassays For Pharmacokinetic Dosing Of Monoclonal Antibodies

    SBC: ABREOS BIOSCIENCES, INC.            Topic: NCI

    DESCRIPTION (provided by applicant): Monoclonal antibodies (mAb) are used to treat a variety of cancers and other diseases. Dosing is typically based on body surface area, but population pharmacokinetic (PK) data suggests considerable variation across patients. Furthermore, there is growing evidence that patients with low final trough levels of circulating antibody have a poorer outcome, suggestin ...

    STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  10. Use of EF2K Inhibitors to Reduce Toxicity to Normal Tissues in Chemotherapy

    SBC: LONGEVICA PHARMACEUTICALS, INC.            Topic: NCI

    DESCRIPTION (provided by applicant): Eukaryotic elongation factor 2 protein kinase (eEF2K) is a ubiquitously expressed protein that belongs to a family of alpha kinases characterized by an atypical kinase domain. Our recent findings demonstrate that inhibition or genetic inactivation of eEF2K protects normal tissues from cytotoxic effects of chemotherapeutic agents and ionizing radiation. We hav ...

    STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government